Azitra (NYSEMKT:AZTR) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents.
This covers the company’s filaggrin-secreting strain of Staphylococcus epidermidis. A patent was issued to it on July 16 by the U.S. Patent and Trademark Office (USPTO). That includes future potential pipeline candidates for indications including atopic dermatitis.
On top of this, Azitra announced three newly allowed patents in the U.S., Canada and China. The U.S. patent covers treating inflammatory skin disease with recombinant microorganisms, the Canada patent covers treating atopic dermatitis with recombinant microorganisms and the China patent also covers treating inflammatory skin disease with recombinant microorganisms.
Azitra Chief Operating Officer Travis Whitfill said the following about the news:
“We are delighted to announce our second US patent issuance this year and three additional patent allowances in key markets in the U.S., Canada, and China. The indication addressed by the newly issued U.S. patent, atopic dermatitis, affects approximately 16.5 million people in the United States.”
AZTR Stock Movement Today
AZTR stock is up 315% as of Tuesday morning. That comes with heavy trading as some 62 million units have changed hands. For the record, its daily average trading volume is only about 100,000 shares.
There are more stock market stories traders will want to read about below!
We have all of the hottest stock market news ready to go on Tuesday! A few examples include what’s going on with spot Ethereum (ETH-USD) exchange-traded funds (ETFs), Serve Robotics (NASDAQ:SERV) stock and Jaguar Health (NASDAQ:JAGX) shares today. All of this news is ready at the links below!
More Tuesday Stock Market News
- Spot Ethereum ETFs: 9 Tickers to Watch as New Funds Start Trading
- Why Is Serve Robotics (SERV) Stock Down Today?
- Why Is Jaguar Health (JAGX) Stock Down 55% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
